Johnson & Johnson/Janssen COVID-19 vaccine to Bolivia, but it cannot move ahead until it is allowed to actually produce it.Biolyse Pharma, an Ontario-based manufacturer, says it already has the capacity to produce up to 20 million doses annually of an already-approved viral-vector COVID-19 vaccine, like the AstraZeneca or Johnson & Johnson vaccines, with the potential to produce 50 million doses.However, it’s unable to do so without a voluntary licence from the patent holder, a compulsory licence through special legislation or the waiving of intellectual property rights.